251
|
Shafran SD. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44:551-6. [PMID: 17224846 DOI: 10.1097/qai.0b013e31803151c7] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Approximately 25% to 35% of HIV-infected persons in developed countries are coinfected with hepatitis C virus (HCV). HCV liver disease is accelerated by HIV coinfection, especially at low CD4 cell counts. Highly active antiretroviral therapy (HAART) dramatically reduces HIV-related mortality, and liver disease has emerged as a major cause of death in HIV/HCV-coinfected persons. Anti-HCV therapy with pegylated interferon plus ribavirin can cure HCV infection in up to 40% of coinfected patients; however, only approximately 10% of coinfected patients are considered candidates. Hence, HCV therapy cures approximately 4% of coinfected patients. Eleven cohort studies have shown that HAART is associated with a reduced rate of progression of HCV liver disease, and 4 of these studies have demonstrated a reduction in liver-related mortality. Although offering HCV therapy to the few eligible HIV/HCV-coinfected patients is important, early initiation of HAART in coinfected patients has a greater public health impact in reducing liver-related mortality than in curing HCV infection in approximately 4% of these patients.
Collapse
Affiliation(s)
- Stephen D Shafran
- Division of Infectious Diseases, Department of Medicine, Walter C. Mackenzie Health Sciences Centre, University of Alberta, 8440-112 Street, Edmonton, Alberta, Canada.
| |
Collapse
|
252
|
Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, Marxuach-Cuétara AM, López-Torres A, Jiménez-Rivera J. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007; 46:613-9. [PMID: 17316873 DOI: 10.1016/j.jhep.2006.12.011] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2006] [Revised: 12/08/2006] [Accepted: 12/11/2006] [Indexed: 01/21/2023]
Abstract
BACKGROUND/AIMS Patients with hepatitis C and human immunodeficiency virus coinfection have rapid fibrosis progression. The effect on fibrosis progression rate and time to cirrhosis of HCV treatment has not been extensively studied. First aim of the study was to assess changes in FPR and TTC and staging after HCV therapy vs. no treatment. Secondary aim was to study changes in FPR/staging of sustained viral responders and non-responders to Peg-IFN alfa-2a and RBV. METHODS Seventy-four (74) co-infected patients were grouped in three according to HCV treatment, Group 1 - None (n=9), Group 2 - IFN (n=30), Group 3-Peg-IFN alfa-2a (n=35). Paired liver biopsies were analyzed and FPR/TTC calculated for each biopsy. RESULTS Baseline characteristics, duration of treatment and time between biopsies were similar among groups. HCV therapy, improved grading, but only Peg-IFN alfa-2a therapy resulted in staging decrease. Group 2 had significant staging increase and Group 1 had doubling of FPR and (TTC) reduction from 22.7 to 9.09 years. Peg-IFN alfa-2a treated patients had negative change in FPR and stabilization in TTC. SVR and NR with Peg-IFN alfa-2a/RBV had same FPR and staging. CONCLUSIONS In patients with HIV/HCV co-infection Peg-IFN alfa 2a based treatment produced regression or stable fibrosis in contrast to accelerated progression in those without treatment.
Collapse
|
253
|
Smith JO, Sterling RK. Hepatitis C and HIV. Curr Gastroenterol Rep 2007; 9:83-90. [PMID: 17335682 DOI: 10.1007/s11894-008-0025-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
HIV and hepatitis C virus (HCV) are global health concerns, and coinfection with these viruses is common due to shared routes of transmission. Mortality rates from AIDS and HIV-associated opportunistic infections have decreased since the institution of highly active antiretroviral therapy, but the incidence of liver-related mortality in coinfected patients has subsequently risen significantly. This increase in progression of liver disease and its subsequent increased mortality have spurred research into the optimization of evaluation and management of the HIV-HCV coinfected patient.
Collapse
Affiliation(s)
- Jenny O Smith
- Section of Hepatology, Virginia Commonwealth University Medical Center, 1200 East Broad Street, Room 1492, Box 908341, Richmond, VA 23298-0341, USA
| | | |
Collapse
|
254
|
Mallet VO, Dhalluin-Venier V, Verkarre V, Correas JM, Chaix ML, Viard JP, Pol S. Reversibility of Cirrhosis in HIV/HBV Coinfection. Antivir Ther 2007. [DOI: 10.1177/135965350701200201] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
HIV infection worsens the course and the natural history of chronic hepatitis B (HBV) leading to rapid progression to cirrhosis and to end-stage liver disease. Highly active antiretroviral therapy (HAART) regimens including nucleoside and/or nucleotide analogues with activity against both HIV reverse transcriptase and hepatitis B virus polymerase have clearly improved the survival rates of HIV/HBV-coinfected patients. How HAART beneficially affects the natural course of chronic hepatitis B in coinfected patients is not known. We report a biopsy-proven case of reversal of HBV-related cirrhosis in a coinfected patient, parallelling long-term suppression of HBV replication with tenofovir disoproxil fumarate as part of a HAART. Pathological reversibility of cirrhosis was ascertained by normalization of biochemical (platelet count) and morphological (abdominal ultrasonography and gastrointestinal endoscopy) tests as well as non-invasive markers of fibrosis. In conclusion, a HAART regimen including tenofovir disoproxil fumarate in a HBV/HIV-coinfected cirrhotic patient might lead to sustained HBV viral suppression and result in cirrhosis reversal.
Collapse
Affiliation(s)
- Vincent O Mallet
- Université Paris-Descartes, Paris, France
- APHP, Hôpital Cochin, Hépatologie, Paris, France
- INSERM U. 567, Institut Cochin, Paris, France
| | | | - Virginie Verkarre
- Université Paris-Descartes, Paris, France
- APHP, Hôpital Necker, Anatomo-Pathologie, Paris, France
| | - Jean-Michel Correas
- Université Paris-Descartes, Paris, France
- APHP, Hôpital Necker, Radiologie, Paris, France
| | - Marie-Laure Chaix
- Université Paris-Descartes, Paris, France
- APHP, Hôpital Necker, Virologie, Paris, France
| | | | - Stanislas Pol
- Université Paris-Descartes, Paris, France
- APHP, Hôpital Cochin, Hépatologie, Paris, France
- INSERM U. 567, Institut Cochin, Paris, France
| |
Collapse
|
255
|
Peribañez Gonzalez M, Guimarães Pessôa M. HIV/HCV coinfection: refining or redefining concepts? Liver Int 2007; 27:1-3. [PMID: 17241374 DOI: 10.1111/j.1478-3231.2006.01413.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
|
256
|
Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A, Ferrari de Oliveira Rigo J, Lerias de Almeida PR, Galperim B, Riegel Santos B. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int 2007; 27:40-6. [PMID: 17241379 DOI: 10.1111/j.1478-3231.2006.01344.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
BACKGROUND/AIMS The objective of the present study is to evaluate the impact of human immunodeficiency virus (HIV) in patients with hepatitis C virus (HCV) infection. METHODS Three different groups of patients were considered: group 1, 385 HCV/HIV coinfected; group 2, 198 HIV monoinfected; and group 3, 311 HCV monoinfected. Demographic and epidemiological data were collected. Blood tests included anti-HCV, HCV-RNA test, genotyping, CD4 cell count, anti-HIV, and HIV viral load. Treatment with interferon and ribavirin was proposed. The fibrosis progression rate was assessed. RESULTS The most prevalent risk factor in the group of coinfected was the use of intravenous drugs; in the HIV monoinfection group, heterosexual relations at risk; in the HCV monoinfection group, the transfusion of blood. There was no difference concerning the distribution of genotypes or HCV viral load between groups 1 and 3. Although the mean time of duration of HCV infection was greater in group 3 than in group 1, there was no difference when the fibrosis progression rate was evaluated. The response to treatment was similar. CONCLUSION In the present series there was no relevant impact of HCV infection in patients with HIV.
Collapse
|
257
|
Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A, van Erpecum KJ, Mauser-Bunschoten EP. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109:3667-71. [PMID: 17213288 DOI: 10.1182/blood-2006-08-038349] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Abstract
Prior to 1990, many patients with inherited bleeding disorders were infected with hepatitis C virus (HCV). This study assessed the risk of end-stage liver disease (ESLD) in patients with hemophilia with chronic hepatitis C. Patients were infected between 1961 and 1990 and were followed up to August 2005. Of 847 anti-HCV+ patients, 160 (19%) spontaneously cleared HCV and 687 (81%) developed chronic hepatitis C. Coinfection with HIV was present in 210 patients. After 35 years of infection the cumulative incidence of ESLD was 11.5% (95% CI, 8.2%-14.8%) in HIV− patients and 35.1% (95% CI, 29.2%-41.0%; P < .001) in patients coinfected with HIV. Independent risk factors of ESLD were HIV coinfection (hazard ratio 13.8; 95% CI, 7.5-25.3), older age at infection (hazard ratio 2.3 per 10 years; 95% CI, 2.0-2.8), alcohol abuse (hazard ratio 4.9; 95% CI, 2.5-9.6), and presence of HCV genotype 1 (hazard ratio 2.2; 95% CI, 1.1-4.2). With longer duration of HCV infection, the risk of developing ESLD is emerging in patients with inherited bleeding disorders. Risk factors for rapid progression to ESLD are alcohol abuse, coinfection with HIV, older age at infection, and presence of HCV genotype 1.
Collapse
Affiliation(s)
- Dirk Posthouwer
- Van Creveldkliniek, University Medical Center Utrecht, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
258
|
Abstract
Many human immunodeficiency virus (HIV) infected persons are coinfected with hepatitis C virus (HCV) and with the use of highly active antiretroviral therapy, liver disease from HCV has become an important cause of morbidity and mortality. The current guidelines recommend that human immunodeficiency virus and HCV coinfected patients be evaluated and treated for HCV if there are no major contraindications to treatment. Coinfected patients treated with pegylated interferon-a and ribavirin have sustained virologic responses (SVRs) of 27% to 40% which for a variety of reasons are lower than those reported in HCV mono-infected patients. Understanding that most patients will not achieve SVRs, strategies to evaluate for the role of maintenance interferon in delaying complications of liver disease are being evaluated. In patients who have failed prior treatment, cannot tolerate treatment, or who have contraindications to HCV treatment, the use of highly active antiretroviral therapy with careful monitoring for hepatotoxicity and aggressive counseling on alcohol and substance abuse may slow down fibrosis progression. As the data on liver transplantation in coinfected patients accumulate, patients with end stage liver disease should be referred early for evaluation in a transplant center. As new drugs for HCV are being developed, it will be of utmost importance to include coinfected patients earlier in the process on new drug trials and therapeutic strategies.
Collapse
Affiliation(s)
- Oluwatoyin M Adeyemi
- Division of Infectious Diseases, CORE Center, Stroger Hospital of Cook County and Rush University Medical Center, Chicago, IL 60612, USA.
| |
Collapse
|
259
|
Abstract
Non-nucleoside reverse transcriptase inhibitors form the backbone of antiretroviral treatment for many HIV-infected individuals. The tolerability, pill burden and efficacy associated with this class of agents make them a frequent choice for first-line therapy. Here we review nevirapine and efavirenz in terms of efficacy, resistance and toxicity, focusing particularly on the use of nevirapine to prevent mother-to-child transmission in developing countries.
Collapse
Affiliation(s)
- L Waters
- Department of HIV/GU Medicine, Chelsea & Westminster Hospital, London, UK
| | | | | |
Collapse
|
260
|
Abstract
Chronic hepatitis C (HCV) infection leads to the development of hepatic fibrosis. No single test for diagnosing liver fibrosis is completely optimal. The ability to assess the extent and progression of fibrosis is important in the clinical setting, especially in the context of current treatments and therapeutic trials. More accurate and noninvasive methods to diagnose and monitor fibrosis are needed, because these trials will require serial evaluations of liver fibrosis to assess a compound's antifibrotic effect.
Collapse
Affiliation(s)
- Efsevia Albanis
- Division of Liver Diseases, Mount Sinai Medical Center, 1425 Madison Avenue, New York, NY 10029, USA
| | | |
Collapse
|
261
|
Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10:697-715. [PMID: 17164113 DOI: 10.1016/j.cld.2006.08.003] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Injection drug use remains the predominant mode of transmission of hepatitis C virus (HCV) infection. Growing numbers of persons who have been chronically infected with HCV for 20 or more years are coming to medical attention and are at risk for serious complications of chronic infection, including cirrhosis and hepatocellular carcinoma. Factors linked with the development of advanced fibrosis and cirrhosis include age at infection, duration of infection, heavy alcohol use, coinfections with HIV or hepatitis B virus, and male sex. Emerging risk factors for disease progression include steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics.
Collapse
Affiliation(s)
- Stephanie R Bialek
- Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
| | | |
Collapse
|
262
|
Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA. Antiretroviral Therapy Based on Protease Inhibitors as a Protective Factor against Liver Fibrosis Progression in Patients with Chronic Hepatitis C. Antivir Ther 2006. [DOI: 10.1177/135965350601100701] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Cohort studies have shown that highly active antiretroviral therapy (HAART) can improve liver-related mortality in HIV/hepatitis C virus (HCV)-coinfected patients. A reduction in the accelerated liver fibrosis progression observed in HIV infection induced by HAART could explain these findings. A few studies have assessed the impact of HAART on liver fibrosis, but with contradictory results. Therefore, we evaluated the associations between the use of different antiretroviral drug classes and HAART combinations, and liver fibrosis in HIV-infected patients with chronic hepatitis C. Six hundred and eighty-three HIV/HCV-coinfected patients, who underwent a liver biopsy and who had not received anti-HCV treatment were included. Age at HCV infection <23 years (adjusted odds ratio [AOR]=0.7, 95% confidence interval [95% CI]=0.3-0.9, P=0.05) and protease inhibitor (PI)-based HAART versus no use of HAART (AOR=0.5, 95% CI=0.3-0.9, P=0.01) were negatively associated with advanced fibrosis (≥F3). PI-based HAART versus no use of HAART (AOR=0.4, 95% CI=0.2-0.7, P=0.001) was negatively associated with fibrosis progression rate ≥0.2 units/year and independently of age at HCV infection and CD4+ T-cell counts. Fifteen (17%) patients treated only with PIs and zidovudine plus lamivudine showed ≥F3, compared with 65 (37%) patients without HAART ( P=0.001). Forty (31%) patients on PI and stavudine plus lamivudine showed ≥F3 ( P=0.3, when compared with patients with no HAART). The use of PI-based HAART in HIV/HCV-coinfected patients is associated with less severe fibrosis and slower progression of fibrosis. The nucleoside analogue backbone in a HAART regimen may influence this association.
Collapse
Affiliation(s)
- Juan Macías
- Hospital Universitario de Valme, Seville, Spain
| | - José A Mira
- Hospital Universitario de Valme, Seville, Spain
| | | | | | | | | | | | | | | | | | - Mónica Trastoy
- Hospitales Universitarios Virgen del Rocío, Seville, Spain
| | | | | | | | | |
Collapse
|
263
|
Lai AR, Tashima KT, Taylor LE. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus. AIDS Patient Care STDS 2006; 20:678-92. [PMID: 17052138 DOI: 10.1089/apc.2006.20.678] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
There is great need to treat HIV/hepatitis C virus (HCV)-coinfected individuals with both antiretroviral and anti-HCV pharmacotherapy. However, treatment for HIV may lead to hepatotoxicity, and there are potential interactions and synergistic effects between antiretrovirals and anti-HCV medications. The ideal antiretroviral therapy options for coinfected patients, in the setting of anti-HCV treatment, are unclear and present important challenges to clinicians. We review the current data on the use of antiretrovirals in HIV/HCV-coinfected patients and offer evidence-based recommendations on optimal selection and dosing of antiretroviral agents for this population.
Collapse
Affiliation(s)
- Andrew R Lai
- Brown Medical School, Providence, Rhode Island, USA
| | | | | |
Collapse
|
264
|
Abstract
PURPOSE OF REVIEW Highly active antiretroviral therapy in coinfected patients is complicated by a potentially increased risk for hepatotoxicity. Therefore, treatment strategies are urgently needed. RECENT FINDINGS In HIV/hepatitis B virus coinfected patients with an indication for therapy for both HIV and hepatitis B, tenofovir plus lamivudine or emtricitabine containing highly active antiretroviral therapy regimens are the favored first-line treatment as they include medications which are dually active. Although highly active antiretroviral therapy has no direct effect on hepatitis C replication, the associated immune restoration appears to slow down the progression of liver fibrosis. In patients with HIV and tuberculosis coinfection without any prior highly active antiretroviral therapy, delay of initiation of antiviral therapy for 4-8 weeks after initiation of tuberculosis treatment allows for a better discrimination of causes of adverse events and paradoxical reactions. SUMMARY With the introduction of new medications for treatment of hepatitis B virus, therapeutic options for HIV/hepatitis B virus coinfected patients have improved considerably. Initiation of highly active antiretroviral therapy may be a promising option for slowing down further progression of hepatitis C-associated liver disease. Simultaneous treatment of tuberculosis and HIV infection remains a therapeutic challenge requiring specific knowledge of drug-drug interactions as well as management strategies for possible immune reconstitution syndromes.
Collapse
|
265
|
Smith JO, Sterling RK. HIV coinfection with hepatitis C and hepatitis B. Curr Infect Dis Rep 2006; 8:409-18. [PMID: 16934201 DOI: 10.1007/s11908-006-0053-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
HIV, hepatitis C virus, and hepatitis B virus are global health concerns. Due to shared routes of transmission, coinfection is common. The incidence of liver-related mortality in coinfected patients has risen significantly since the inception of highly active antiretroviral therapy, a treatment that has helped decreased mortality rates from AIDS and opportunistic infections. This trend has led to increased research into the evaluation and management of the coinfected patient. This article details the principles of successful management of this challenging patient population.
Collapse
Affiliation(s)
- Jenny O Smith
- Section of Hepatology, Virginia Commonwealth University Medical Center, 1200 E Broad Street, Room 1492, Box 908341, Richmond, VA 23298-0341, USA.
| | | |
Collapse
|
266
|
Abstract
Treatment of HCV in the coinfected patient poses numerous challenges to the clinician: difficult comorbidities, an increased risk of medication side effects, and a therapy with limited response rates. End-stage liver disease from HCV has become a leading cause of death in coinfected patients. Without focused disease management, the burden of chronic liver disease in this population will rise. This article discusses the major trials investigating the use of interferon and ribavirin in coinfected patients, proposes a treatment algorithm for HCV/HIV coinfection, and considers approaches to patients who do not respond to this treatment.
Collapse
Affiliation(s)
- Karin Andersson
- Department of Gastroenterology, Blake 4, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
| | | |
Collapse
|